Chlorthalidone

Generic Name: Chlorthalidone

Brand Names: Edarbyclor, Tenoretic, Thalitone

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₁ClN_₂O_₄S

CAS Number: 77-36-1

Unique Ingredient Identifier: Q0MQD1073Q

Background: Chlorthalidone is a thiazide-like diuretic used for the treatment of hypertension and for management of edema caused by conditions such as heart failure or renal impairment. Chlorthalidone improves blood pressure and swelling by preventing water absorption from the kidneys through inhibition of the Na+/Cl− symporter in the distal convoluted tubule cells in t...

Indication: Chlorthalidone is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension.

Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy....

Associated Conditions: Calcium Nephrolithiasis, Edema, Hypertension

Associated Therapies: -

Clinical Trials

The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone

Phase 4

Withdrawn

Conditions: Resistant Hypertension in Kidney Transplant Patients

Interventions: Drug: Chlorthalidone

First Posted Date: 2014-01-08

Last Posted Date: 2017-06-15

Lead Sponsor: Virginia Commonwealth University

Registration Number: NCT02030314

Locations: 🇺🇸
Virginia Commonwealtlh University, Richmond, Virginia, United States

A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD

Phase 4

Completed

Conditions: Chronic Kidney Disease
Poorly-Controlled Hypertension

First Posted Date: 2012-12-17

Last Posted Date: 2016-06-13

Lead Sponsor: Indiana University

Target Recruit Count: 14

Registration Number: NCT01750294

Locations: 🇺🇸
Richard L. Roudebush VAMC, Indianapolis, Indiana, United States

EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network

Phase 4

Withdrawn

Conditions: Hypertension

Interventions: Drug: Chlorthalidone
Drug: Hydrochlorothiazide

First Posted Date: 2012-12-12

Last Posted Date: 2017-08-18

Lead Sponsor: Johns Hopkins University

Registration Number: NCT01748123

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

Phase 4

Terminated

Conditions: Hypertension
Stage 2 Hypertension
Diabetes

Interventions: Drug: Valturna
Drug: Placebo of Valturna Tablet
Drug: Chlorthalidone
Drug: Amlodipine
Drug: Placebo Capsule

First Posted Date: 2011-06-08

Last Posted Date: 2013-03-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 975

Registration Number: NCT01368536

Locations: 🇵🇷
Novartis Investigative Site, San Juan, Puerto Rico

Pharmacogenomic Evaluation of Antihypertensive Responses 2

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: Metoprolol
Drug: Chlorthalidone

First Posted Date: 2010-09-16

Last Posted Date: 2018-04-06

Lead Sponsor: University of Florida

Target Recruit Count: 839

Registration Number: NCT01203852

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸
Mayo Clinic, Division of Hypertension, Rochester, Minnesota, United States

Resistant Arterial Hypertension Cohort Study

Completed

Conditions: Essential Hypertension
Resistant Hypertension
Hypertension

Interventions: Behavioral: motivational intervention for non-compliant individuals
Drug: standardized anti-hypertensive treatment
Drug: chlorthalidone

First Posted Date: 2010-03-09

Last Posted Date: 2018-10-30

Lead Sponsor: University Hospital, Geneva

Target Recruit Count: 74

Registration Number: NCT01083017

Locations: 🇨🇭
Geneva University Hospitals, Geneva, Switzerland
🇨🇭
Kantonsspital Luzern, Luzern, Switzerland
🇨🇭
Lausanne University Hospital, CHUV, Lausanne, Switzerland

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Azilsartan medoxomil and chlorthalidone
Drug: Chlorthalidone
Drug: Azilsartan medoxomil

First Posted Date: 2009-02-19

Last Posted Date: 2012-02-07

Lead Sponsor: Takeda

Target Recruit Count: 1711

Registration Number: NCT00847626

Efficacy and Safety of Azilsartan Medoxomil Co-Administered With Chlorthalidone in Participants With Essential Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Azilsartan medoxomil and chlorthalidone
Drug: Chlorthalidone

First Posted Date: 2008-01-11

Last Posted Date: 2011-04-19

Lead Sponsor: Takeda

Target Recruit Count: 551

Registration Number: NCT00591773

Uric Acid and Hypertension in African Americans

Phase 3

Completed

Conditions: Cardiovascular Diseases
Heart Diseases
Hypertension

Interventions: Drug: Placebo
Drug: Allopurinol
Drug: Chlorthalidone
Drug: Potassium chloride

First Posted Date: 2005-10-19

Last Posted Date: 2013-07-26

Lead Sponsor: University of Florida

Target Recruit Count: 150

Registration Number: NCT00241839

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States

Hypertension Screening and Treatment Program

Completed

Conditions: Hypertension

First Posted Date: 2001-01-01

Last Posted Date: 2009-01-21

Lead Sponsor: US Department of Veterans Affairs

Registration Number: NCT00007592

Locations: 🇺🇸
Vamc - Jackson, Jackson, Mississippi, United States
🇺🇸
Vamc - Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Vamc - Iowa City, Iowa City, Iowa, United States

and more 9 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy